The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial

References

• Maricic M, Gluck O. Review of raloxifene and its clinical applications in osteoporosis. Expert Opin Pharmacother 2002;3:767–75
   PubMedGoogle Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609–17
   PubMed Web of Science ®Google Scholar
• Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140–3
   PubMed Web of Science ®Google Scholar
• Cooper C, O’Neill T, Silman A. The epidemiology of vertebral fractures [European Vertebral Osteoporosis Study Group]. Bone 1993;14\(Suppl 1)S89–S97
   Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. J Am Med Assoc 2001;285:320–3
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793–800
   PubMed Web of Science ®Google Scholar
• Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study [Study of Osteoporotic Fractures Research Group]. Arch Intern Med 1999;159:1215–20
   PubMed Web of Science ®Google Scholar
• Grady D, Ettinger B, Moscarelli E, et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol 2004;104:837–44
   Google Scholar
• Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137–48
   PubMed Web of Science ®Google Scholar
• Anon. StatXact5 user manual. Cambridge (MA): 2001;515–7
   Google Scholar
• Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468–89
   PubMed Web of Science ®Google Scholar
• Delmas PD, Genant HK, Crans G, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522–32
   PubMed Web of Science ®Google Scholar
• Siris E, Adachi JD, Lu Y, et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int 2002;13:907–13
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy With Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433–9
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118–24
   PubMed Web of Science ®Google Scholar
• Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34:599–604
   PubMed Web of Science ®Google Scholar
• Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodelling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985–92
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ, III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17:11–4
   Google Scholar
• Heaney RP. Is the paradigm shifting? Bone 2003;33:457–65
   PubMed Web of Science ®Google Scholar